Current strategies for ischemic stroke prevention: role of multimodal combination therapies.
Stroke remains a global leading cause of death and long-term disability, highlighting the need for more effective treatment approaches. The majority of strokes are of ischemic origin, often caused by large- or small-artery atherothrombosis, or cardioembolism. Considering the systemic nature of the atherothrombotic disease process, stroke patients are at increased risk for ischemic events in several vascular territories: cerebral, coronary and peripheral. Due to the limited options for acute stroke therapies, stroke prevention is an important therapeutic approach. In addition to the management of modifiable risk factors such as hypertension, dyslipidemia and smoking through pharmacotherapy or lifestyle adjustments, anticoagulants, surgical and perhaps endovascular approaches are indicated in certain patients. Antiplatelet therapies using various agents are a cornerstone of secondary stroke prevention. To ensure the appropriate continuum of care after hospitalization for ischemic stroke, some interventions for the prevention of recurrent ischemic stroke should be initiated during the acute hospitalization setting and maintained in the out-patient setting.
Alberts
M J
MJ
Dept. of Neurology, Northwestern University, Feinberg School of Medicine, 710 North Lake Shore Drive, Room 1420, Chicago, IL 60611, USA. m-alberts@northwestern.edu
Ovbiagele
B
B
D000959:Antihypertensive Agents; D003131:Combined Modality Therapy; D005343:Fibrinolytic Agents; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007511:Ischemia / Q000150:complications; D012307:Risk Factors; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*; D010959:Tissue Plasminogen Activator
D000959:Antihypertensive Agents; D005343:Fibrinolytic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010959:Tissue Plasminogen Activator